Personalis, Inc. (PSNL)
After hours:
| Previous close | 1.4500 |
| Open | 1.4500 |
| Bid | 1.3200 x 300 |
| Ask | 1.3800 x 200 |
| Day's range | 1.3400 - 1.4550 |
| 52-week range | 0.8910 - 2.5900 |
| Volume | |
| Avg. volume | 265,188 |
| Market cap | 70.117M |
| Beta (5Y monthly) | 1.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9000 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.60 |
Business WireASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
FREMONT, Calif., June 04, 2024--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring. The NeXT Personal test is the first of a new class of ultra-sensitive liquid biopsy tests designed to detect the earliest traces of cancer recurrence and
Business WirePersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
FREMONT, Calif., May 31, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus’ commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung cancers
Business WirePersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
FREMONT, Calif., May 22, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois.
